Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Williams, N. Poulter, Morris Brown, M. Davis, G. Mcinnes, J. Potter, P. Sever, S. Thom (2004)
Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IVJournal of Human Hypertension, 18
E. Lewis, L. Hunsicker, W. Clarke, T. Berl, M. Pohl, J. Lewis, E. Ritz, R. Atkins, R. Rohde, I. Raz (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.The New England journal of medicine, 345 12
R. Turner, R. Holman (1998)
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.BMJ
M. Weber, H. Black, G. Bakris, H. Krum, S. Linas, Robert Weiss, J. Linseman, B. Wiens, M. Warren, L. Lindholm (2009)
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trialThe Lancet, 374
A. Whaley-Connell, J. Sowers, D. Purkayastha (2010)
Combination therapy with aliskiren and HCTZ decreases plasma renin activity and oxidative stress vs ramipril while reducing blood pressure in obese patients with stage 2 hypertension [abstract no. PO-66]J Clin Hypertens, 12
A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, Daniel Jones, B. Materson, S. Oparil, J. Wright, E. Roccella (2003)
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.Hypertension, 42 6
J.R. Sowers, M. Epstein (1995)
Diabetes mellitus and associated hypertension, vascular disease, and nephropathyHypertension, 26
J.D. Curb, S.L. Pressel, J.A. Cutler (1996)
Effect of diuretic-based antihypertensive treatment of cardiovascular disease risk in older diabetic patients with isolated systolic hypertensionJAMA, 276
R.R. Townsend, A. Forker, P. Rumpelt (2010)
Initial combination therapy with aliskiren/hydrochlorothiazide is more effective than amlodipine in patients with stage 2 systolic hypertension and diabetes mellitus [abstract no. LB-PO-03]J Clin Hypertens, 12
S. Oparil, S. Yarows, Samir Patel, Hui Fang, J. Zhang, A. Satlin (2007)
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trialThe Lancet, 370
M. Stearne, S. Palmer, M. Hammersley, S. Franklin, R. Spivey, J. Levy, C. Tidy, N. Bell, J. Steemson, B. Barrow, R. Coster, K. Waring, J. Nolan, E. Truscott, N. Walravens, L. Cook, H. Lampard, C. Merle, P. Parker, J. Mcvittie, I. Draisey, L. Murchison, A. Brunt, M. Williams, D. Pearson, X. Petrie, M. Lean, D. Walmsley, M. Lyall, E. Christie, J. Church, E. Thomson, A. Farrow, J. Stowers, M. Stowers, K. McHardy, N. Patterson, A. Wright, N. Levi, A. Shearer, R. Thompson, G. Taylor, S. Rayton, M. Bradbury, A. Glover, A. Smyth-Osbourne, C. Parkes, J. Graham, P. England, S. Gyde, C. Eagle, B. Chakrabarti, J. Smith, J. Sherwell, E. Kohner, A. Dornhurst, M. Doddridge, M. Dumskyj, S. Walji, P. Sharp, M. Sleightholm, G. Vanterpool, C. Rose, G. Frost, M. Roseblade, S. Elliott, S. Forrester, M. Foster, K. Myers, R. Chapman, J. Hayes, R. Henry, M. Featherston, G. Archbold, M. Copeland, R. Harper, I. Richardson, S. Martín, H. Davison, D. Hadden, L. Kennedy, A. Atkinson, A. Culbert, C. Hegan, H. Tennet, N. Webb, I. Robinson, J. Holmes, P. Bell, D. McCance, J. Rutherford, S. Nesbitt, A. Spathis, S. Hyer, M. Nanson, L. James, J. Tyrell, C. Davis, P. Strugnell, M. Booth, H. Petrie, D. Clark, B. Rice, S. Hulland, J. Barron, J. Yudkin, B. Gould, J. Singer, A. Badenock, M. Eckert, K. Alibhai, E. Marriot, C. Cox, R. Price, M. Fernandez, A. Ryle, S. Clarke, G. Wallace, E. Mehmed, S. Macfarlane, R. Greenwood, J. Wilson, M. Denholm, R. Temple, K. Whitfield, F. Johnson, C. Munroe, S. Gorick, E. Duckworth, M. Flatman, S. Rainbow, L. Borthwick, D. Wheatcroft, R. Seaman, R. Christie, W. Wheatcroft, P. Musk, J. White, S. McDougal, M. Bond, P. Raniga, R. Newton, R. Jung, C. Roxburgh, B. Kilgallon, L. Dick, N. Waugh, S. Kilby, A. Ellingford, J. Burns, C. Fox, M. Holloway, H. Coghill, N. Hein, A. Fox, W. Cowan, M. Richard, K. Quested, S. Evans, R. Paisey, N. Brown, A. Tucker, R. Paisey, F. Garrett, J. Hogg, P. Park, K. Williams, Philip Harvey, R. Wilcocks, S. Mason, J. Frost, C. Warren, P. Rocket, L. Bower, J. Roland, D. Brown, J. Youens, K. Stanton-King, H. Mungall, W. Maddison, D. Donnelly, S. King, P. Griffin, S. Smith, S. Church, G. Dunn, Apr Wilson, K. Palmer, P. Brown, D. Humphriss, A. Davidson, R. Rose, L. Armistead, S. Townsend, P. Poon, I. Peacock, N. Culverwell, M. Charlton, B. Connolly, J. Peacock, J. Barrett, J. Wain, W. Beeston, G. King, P. Hill, A. Boulton, A. Robertson, Katoulis, A. Olukoga, H. McDonald, S. Kumar, F. Abouaesha, B. Abuaisha, E. Knowles, S. Higgins, J. Booker, J. Sunter, K. Breislin, R. Parker, P. Raval, J. Curwell, H. Davenport, G. Shawcross, A. Prest, J. Grey, H. Cole, C. Sereviratne, R. Young, T. Dornan, J. Clyne, M. Gibson, I. O'Connell, L. Wong, S. Wilson, K. Wright, C. Wallace, D. McDowell, A. Burden, E. Sellén, R. Gregory, M. Roshan, N. Vaghela, M. Burden, C. Sherriff, J. Clarke, J. Grenfell, J. Tooke, K. Macleod, C. Searnark, M. Rammell, C. Pym, J. Stockman, C. Yeo, J. Piper, L. Leighton, E. Green, M. Hoyle, K. Jones, A. Hudson, A. James, A. Shore, A. Higham, B. Martin (1998)
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ, 317
F. Messerli, Ehud Grossman, U. Goldbourt (2001)
Antihypertensive therapy in diabetic hypertensive patients.American journal of hypertension, 14 5 Pt 2
A. Gradman, R. Schmieder, R. Lins, J. Nussberger, Y. Chiang, M. Bedigian (2005)
Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive PatientsCirculation, 111
F. Zieve, A. Yadao, C. Yurkovic, S. Kandala, G. Ledesma (2010)
ALISKIREN WITH OR WITHOUT HYDROCHLOROTHIAZIDE LOWERS BLOOD PRESSURE EFFECTIVELY IN PATIENTS WITH STAGE 2 HYPERTENSION AND METABOLIC SYNDROME: PP.38.505Journal of Hypertension, 28
Tetsuya Hayashi, S. Takai, C. Yamashita (2010)
Impact of the Renin-Angiotensin-Aldosterone-System on Cardiovascular and Renal Complications in Diabetes MellitusCurrent Vascular Pharmacology, 8
J. Pool, R. Schmieder, M. Azizi, J. Aldigier, A. Januszewicz, W. Zidek, Y. Chiang, A. Satlin (2007)
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.American journal of hypertension, 20 1
J. Sowers, M. Epstein, E. Frohlich (2001)
Diabetes, Hypertension, and Cardiovascular Disease: An UpdateHypertension: Journal of the American Heart Association, 37
H. Parving, B. Brenner, J. McMurray, D. Zeeuw, S. Haffner, S. Solomon, N. Chaturvedi, M. Ghadanfar, N. Weissbach, Zhihua Xiang, J. Armbrecht, M. Pfeffer (2009)
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 24 5
Y. Uresin, Addison Taylor, C. Kilo, D. Tschöpe, M. Santonastaso, G. Ibram, Hui Fang, A. Satlin (2007)
Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertensionJournal of the Renin-Angiotensin-Aldosterone System, 8
F. Persson, P. Rossing, H. Reinhard, T. Juhl, C. Stehouwer, C. Schalkwijk, A. Danser, F. Boomsma, E. Frandsen, H. Parving (2009)
Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and AlbuminuriaDiabetes Care, 32
J. Jordan, S. Engeli, Sam Boye, S. Breton, D. Keefe (2007)
Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial HypertensionHypertension, 49
J. Curb, S. Pressel, J. Cutler, P. Savage, W. Applegate, H. Black, G. Camel, BARRY David, PHILLIP Frost, N. Gonzalez, G. Guthrie, A. Oberman, G. Rutan, A. Adams (1996)
Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.JAMA, 276 23
A. Whaley-Connell, B. Pavey, P. McCullough, G. Saab, Suying Li, Samy McFarlane, Shu‐Cheng Chen, J. Vassalotti, A. Collins, G. Bakris, J. Sowers (2010)
Dysglycemia Predicts Cardiovascular and Kidney Disease in the Kidney Early Evaluation ProgramThe Journal of Clinical Hypertension, 12
F. Messerli, S. Bangalore (2009)
Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark?Circulation, 119 3
Fadi El-Atat, Samy McFarlane, J. Sowers (2004)
Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and managementCurrent Hypertension Reports, 6
A. Villamil, S. Chrysant, D. Calhoun, Bonnie Schober, H. Hsu, Linda Matrisciano-Dimichino, J. Zhang (2007)
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazideJournal of Hypertension, 25
B. Brenner, M. Cooper, D. Zeeuw, W. Keane, W. Mitch, H. Parving, G. Remuzzi, S. Snapinn, Zhonxin Zhang, S. Shahinfar (2001)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.The New England journal of medicine, 345 12
S. Chrysant (2008)
Aliskiren–hydrochlorothiazide combination for the treatment of hypertensionExpert Review of Cardiovascular Therapy, 6
R. Schmieder, T. Philipp, J. Guerediaga, M. Gorostidi, Beverly Smith, N. Weissbach, M. Maboudian, J. Botha, H. Ingen (2009)
Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren: A 12-Month Randomized, Double-Blind Comparator Trial With HydrochlorothiazideCirculation, 119
P. Tatti, M. Pahor, R. Byington, P. Mauro, R. Guarisco, G. Strollo, F. Strollo (1998)
Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDMDiabetes Care, 21
L. Hansson, A. Zanchetti, S. Carruthers, B. Dahlöf, D. Elmfeldt, S. Julius, J. Ménard, K. Rahn, H. Wedel, S. Westerling (1998)
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialThe Lancet, 351
C. Arauz-Pacheco, Marian Parrott, P. Raskin (2003)
Treatment of hypertension in adults with diabetes.Diabetes care, 26 Suppl 1
J. Sowers, Murray Epstein (1995)
Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update.Hypertension, 26 6 Pt 1
H. Parving, F. Persson, J. Lewis, E. Lewis, N. Hollenberg (2008)
Aliskiren combined with losartan in type 2 diabetes and nephropathy.The New England journal of medicine, 358 23
N. Chapman, J. Dobson, Sarah Wilson, B. Dahlöf, P. Sever, H. Wedel, N. Poulter (2007)
Effect of Spironolactone on Blood Pressure in Subjects With Resistant HypertensionHypertension, 49
D. Müller, F. Luft (2006)
Direct renin inhibition with aliskiren in hypertension and target organ damage.Clinical journal of the American Society of Nephrology : CJASN, 1 2
G. Bakris, J. Sowers (2008)
ASH Position Paper: Treatment of Hypertension in Patients With Diabetes—An UpdateThe Journal of Clinical Hypertension, 10
A. Levey, J. Coresh, K. Bolton, B. Culleton, K. Harvey, T. Ikizler, C. Johnson, A. Kausz, P. Kimmel, J. Kusek, A. Levin, K. Minaker, R. Nelson, H. Rennke, M. Steffes, B. Witten, R. Hogg, S. Furth, K. Lemley, R. Portman, G. Schwartz, J. Lau, E. Balk, R. Perrone, T. Karim, Lara Rayan, Inas Al-Massry, P. Chew, B. Astor, De Vine, G. Eknoyan, N. Levin, S. Burrows‐Hudson, W. Keane, A. Kliger, D. Latos, D. Mapes, E. Oberley, K. Willis, G. Bailie, G. Becker, J. Burrowes, D. Churchill, A. Collins, W. Couser, D. Dezeeuw, A. Garber, T. Golper, F. Gotch, A. Gotto, J. Greer, R. Grimm, R. Hannah, J. Acosta, L. Hunsicker, M. Klag, S. Klahr, C. Lewis, E. Lowrie, A. Matas, S. McCulloch, Maureen Michael, J. Nally, J. Newmann, A. Nissenson, Keith Norris, W. Owen, T. Patel, G. Payne, R. Rivera-Mizzoni, David Smith, R. Star, T. Steinman, F. Valderrábano, J. Walls, J. Wauters, N. Wenger, J. Briggs (2002)
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.American journal of kidney diseases : the official journal of the National Kidney Foundation, 39 2 Suppl 1
Am J Cardiovasc Drugs 2011; 11 (5): 327-333 ORIGINAL RESEARCH ARTICLE 1175-3277/11/0005-0327/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination A Placebo-Controlled Study 1 2 3 4 5 W. Drummond, Y.M. Sirenko, E. Ramos, I. Baek and D.L. Keefe 1 Renaissance Clinical Research and Hypertension Center, Dallas, TX, USA 2 Institute of Cardiology, Kyiv, Ukraine 3 Department of Medicine, University of Seville, Seville, Spain 4 Novartis Pharma AG, Basel, Switzerland 5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Abstract Background: Hypertension frequently coexists with diabetes mellitus, resulting in increased cardiovascular risk. Thus, BP control is crucial in decreasing morbidity and mortality in this difficult-to-treat patient population. Objective: The objective of this study was to evaluate the efficacy and safety of aliskiren in hypertensive patients with diabetes not adequately responsive to the combination of valsartan and hydrochlorothiazide (HCT). Methods: After a 1- to 4-week washout period, patients with a mean sitting diastolic BP (msDBP) ‡95 mmHg were treated with valsartan 160 mg for 2 weeks followed by valsartan/HCT 160 mg/25 mg for an additional 4 weeks (single-blind active run-in period). Patients whose msDBP
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 17, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.